Clinical trial
A Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared With Physician's Best Choice in HER2-Negative Breast Cancer Patients With Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD)
NCT03613181 is registered in ClinicalTrials.gov with Angiochem Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Open-Label, Multi-Center Pivotal Study of ANG1005 Compared With Physician's Best Choice in HER2-Negative Breast Cancer Patients With Newly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD)
- Lead sponsor
- Angiochem Inc
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- December 31, 2023
- Completion date
- December 31, 2024
- Enrollment
- 150 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
brain metastases, her2-negative breast cancer, leptomeningeal carcinomatosis, leptomeningeal metastases